93 related articles for article (PubMed ID: 9533649)
1. (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors.
Moody TW; Leyton J; Unsworth E; John C; Lang L; Eckelman WC
Peptides; 1998; 19(3):585-92. PubMed ID: 9533649
[TBL] [Abstract][Full Text] [Related]
2. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
4. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
5. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
6. VIP and breast cancer.
Moody TW; Leyton J; Gozes I; Lang L; Eckelman WC
Ann N Y Acad Sci; 1998 Dec; 865():290-6. PubMed ID: 9928023
[TBL] [Abstract][Full Text] [Related]
7. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeling and in vitro and in vivo characterization of [18F]FB-[R(8,15,21), L17]-VIP as a PET imaging agent for tumor overexpressed VIP receptors.
Cheng D; Yin D; Li G; Wang M; Li S; Zheng M; Cai H; Wang Y
Chem Biol Drug Des; 2006 Dec; 68(6):319-25. PubMed ID: 17177894
[TBL] [Abstract][Full Text] [Related]
9. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
Gespach C; Bawab W; de Cremoux P; Calvo F
Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies.
Pallela VR; Thakur ML; Chakder S; Rattan S
J Nucl Med; 1999 Feb; 40(2):352-60. PubMed ID: 10025846
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
Moody TW; Zia F; Makheja A
Peptides; 1993; 14(2):241-6. PubMed ID: 8387187
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.
De Maria S; Metafora S; Metafora V; Morelli F; Robberecht P; Waelbroeck M; Stiuso P; De Rosa A; Cozzolino A; Esposito C; Facchiano A; Cartenì M
Eur J Biochem; 2002 Jul; 269(13):3211-9. PubMed ID: 12084061
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.
Moody TW; Mantey SA; Fuselier JA; Coy DH; Jensen RT
Peptides; 2007 Sep; 28(9):1883-90. PubMed ID: 17580098
[TBL] [Abstract][Full Text] [Related]
18. VIP-ellipticine derivatives inhibit the growth of breast cancer cells.
Moody TW; Czerwinski G; Tarasova NI; Michejda CJ
Life Sci; 2002 Jul; 71(9):1005-14. PubMed ID: 12088760
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Collado B; Prieto JC; Bajo AM
Regul Pept; 2007 Dec; 144(1-3):101-8. PubMed ID: 17683807
[TBL] [Abstract][Full Text] [Related]
20. Identification of a VIP-specific receptor in guinea pig tenia coli.
Teng BQ; Grider JR; Murthy KS
Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G718-25. PubMed ID: 11518684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
